RxDoctor Payments DataLook up a doctor →

Eyob Makonnen

Endocrinology, Diabetes & Metabolism · Annapolis, MDNPI 1396904207

Payments from drug & device makers

$204,818in general payments, 2019–2025

Across 708 payments — averaging $289.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$156K
  • Abbott$42K
  • Novo Nordisk$1K
  • Amgen$694
  • Sanofi-aventis U.S. LLC$599
  • AstraZeneca$564
  • plus $4K from 38 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC290$155,674
Abbott89$42,180
Novo Nordisk66$1,221
Amgen(2 entities)29$694
Sanofi-aventis U.S. LLC23$599
AstraZeneca(2 entities)27$564
Xeris Pharmaceuticals, Inc.29$437
Insulet Corporation15$405
Boehringer Ingelheim18$368
Medtronic(2 entities)14$313
Bayer11$218
Cequr Corporation3$196
Corcept Therapeutics8$193
Amneal Pharmaceuticals LLC9$171
Dexcom, Inc.7$170
AbbVie8$161
Radius Health, Inc.6$149
Amphastar Pharmaceuticals, Inc.6$109
Mannkind Corporation6$90
Ascendis Pharma Endocrinology Inc3$75
IBSA Pharma Inc.4$74
Neurocrine Biosciences, Inc.2$66
Merck4$66
Tandem Diabetes Care, Inc.3$62
Pfizer3$51
BD2$49
BETA Bionics, Inc.3$41
Verity Pharmaceuticals Inc.2$40
Sequel Med Tech, LLC2$39
Antares Pharma, Inc.2$34
Novartis1$32
Johnson & Johnson1$31
Enterra Medical, Inc.1$30
Embecta Corp.1$27
Madrigal Pharmaceuticals1$27
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$25
Averitas Pharma Inc.1$23
GSK1$19
Braintree Laboratories, Inc.1$18
Amarin Pharma, Inc.1$17
Recordati_rare_diseases_inc.1$17
Halozyme Inc1$16
RGH Enterprises LLC1$15
Lifescan, Inc.1$13

How this compares

$204,818 in reported general payments places this provider in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.

See all endocrinology, diabetes & metabolism providers in Maryland →

Medicare billing

Part B allowed, 2024
$257,383
Medicare patients
804
Services billed
2,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Annapolis

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →